Hematopoietic cell transplantation (HCT) is a highly specialized, expensive and resource-intense medical procedure that can be associated with racial disparities. We review the prevailing literature on racial disparities in HCT in the United States and describe areas for future research and interventions. We discuss the complexity of interpreting race as a biological and social determinant of disease in biomedical research, especially as it relates to HCT. In the United States, race is often a surrogate for socioeconomic, education and health insurance status. We also discuss some of the nuances to consider while reviewing the literature on racial disparities. Disparities by race exist in three areas related to HCT: donor availability, access to HCT and outcomes of HCT. African-Americans/Blacks have a lower likelihood of finding an unrelated donor. Race and ethnicity definitions are country-specific and reconciling race data can represent significant challenges to unrelated donor registries worldwide. African-Americans/Blacks do not have the same access to autologous and allogeneic HCT as Whites. Racial disparities in outcomes of HCT are more prevalent among allogeneic HCT than autologous HCT recipients. More research is required to understand the biological, social, cultural, medical and financial aspects of race that may influence access to HCT and survival after transplantation. Better understanding of racial disparities will minimize inequities, inform health policy, guide development of interventions targeted to eliminate disparities and ensure equitable access to HCT for all populations.
INTRODUCTION
The utilization of hematopoietic cell transplantation (HCT) continues to increase over time. 1 However, HCT is a highly specialized, technologically sophisticated, resource-intense and expensive procedure that is available at select centers in the country. Given its restricted availability, it can be associated with disparities in access and outcomes for minority populations. 2 In this paper, we review the concept of race and ethnicity in biomedical research in the United States, including the challenges of associating race with biology of disease and the role of race as a social construct in medicine. We describe some issues that have to be considered when interpreting the research on racial disparities, especially as it relates to HCT. We also review the available literature on racial disparities in HCT and describe areas for future research and interventions.
RACE AND ETHNICITY IN MEDICINE
Race is considered to be a sociopolitical construct that is based on the geographic region of origin of an individual's ancestry. 3 The 2010 US census categorized race into five broad categories, based on guidance provided by the US Office of Management and Budget: White, Black or African-American (henceforth, referred to as Black), American-Indian or Alaska Native, Asian and Native Hawaiian or Other Pacific Islander. 4 A related concept is ethnicity, which is considered to be a broader construct that takes into account cultural tradition, common history, religion and often a shared genetic heritage. 3 The 2010 US census enquired about ethnic background and asked respondents to identify whether they were of Hispanic, Latino or Spanish origin. 4 The use of race and ethnicity as a determinant of disease risk and outcome is very prevalent in biomedical research. However, there is considerable debate about the biological relevance of race. Some researchers have argued that because there is no basis in the genetic code for race, it serves as a flawed surrogate for multiple environmental and genetic factors in disease causation, and some have gone as far as suggesting that racial classifications be excluded from biomedical research. 5, 6 At the other end of the spectrum, researchers argue that despite the genetic homogeneity of the human race, there exists considerable genetic variation among populations that is geographically structured, and as race is correlated with geography, there is some value to investigating the association of race and disease. 7, 8 At the same time, because humans have been only partially isolated by geography, substantial overlap occurs between populations, and even proponents of studying race in medicine suggest careful and thoughtful interpretation of studies on the biological implications of race.
Race is an important social determinant of health. In the United States, race and ethnic background are strongly correlated with socioeconomic status and health insurance coverage, and hence, are robust predictors of access to and quality of healthcare. 3, 9, 10 However, even when other health-care access-related factors are the same (for example, ability to pay for care), racial and ethnic minorities still receive lower quality of health care than Whites. 10, 11 Disparities in healthcare, which are defined as racial or ethnic differences in the quality of health care that are not due to accessrelated factors or clinical needs, preferences and appropriateness of intervention, result in poor overall health status among minority populations (for example, Blacks and Hispanics) compared with nonminority populations (for example, Whites). 9 Racial disparities have been well documented among cancer patients in the United States. 12 --17 Blacks have the highest death rate and shortest survival of any racial and ethnic group in the United States for most cancers. 18 The causes of these inequalities are thought to be complex and multifactorial, and likely reflect social and economic disparities more than biologic differences. Racial minorities with cancer are more likely to belong to lower socioeconomic strata, be under-or un-insured, and have lower levels of health literacy and education. 12, 18, 19 Also, physicians and providers may have race-based biases and beliefs about cancer treatments. 12 Health-care system, organizational and structural factors, reimbursement and financial forces can also contribute to racial disparities in cancer care. 12 Issues to consider while interpreting the literature on racial disparities When reviewing studies of race and ethnicity in biomedical research, several issues have to be considered. 20 These include:
(1) Race is more of a social than biological construct. 
RACE AND ETHNICITY IN HCT
Certain aspects of HCT make it particularly susceptible to racial and ethnic disparities in access and outcomes. 2 Racial inequalities in healthcare are closely associated with socioeconomic and educational status, and health insurance coverage. Because HCT is an expensive and sophisticated procedure, socioeconomic and health literacy factors may be relevant in contributing to racial disparities. These factors may contribute to other social barriers, such as availability of caregivers and transportation as well as patient adherence (for example, related to high out-of-pocket deductibles for outpatient medications). For recipients of allogeneic HCT, the need for a diverse donor pool adds to race-related disparities.
Race and donor availability A unique aspect of allogeneic HCT is the need for appropriately HLAmatched donors. About 70% of patients who need allogeneic HCT do not have a matched sibling and must rely on unrelated donors or umbilical cord blood (UCB). The distribution of HLA types in the human population is extremely diffuse and differs by ancestry. Although there is substantial overlap between these distributions, the likelihood of matching between two randomly selected individuals is higher if they are of the same race, which can on sometimes be a very crude surrogate for genetic ancestry. 23, 24 The National Marrow Donor Program's (NMDP) Be The Match Registry has about 9 million potential donors. Whites constitute nearly 6.5 million (74%) donors in the registry, whereas the representation of Hispanics (10%), Blacks (7%) and Asians (7%) is less frequent. 25 The probability of finding a match within the registry is estimated to be 0.93 for Whites, 0.82 for Hispanics, 0.77 for Asian Americans and 0.58 for Blacks. HCT recipients are more likely to match to a donor of the same race and ethnicity. 23 The NMDP has a number of ongoing initiatives to increase the diversity of its donor pool and to increase the representation of racial and ethnic minorities in its registry. These programs have resulted in a greater proportion of patients from the racial groups receiving unrelated donor allogeneic HCT over time. 25 However, availability of suitably HLA-matched unrelated donors continues to be a barrier to HCT among these populations.
As UCB transplantation can be successfully performed with partially HLA-matched units, it has the potential to increase the odds of finding an appropriate donor for patients from racial and ethnic minority populations. Recognizing this need, the NMDP has been actively working on increasing the repertoire of racially diverse UCB units available through its network of UCB banks. In 2010, over 40% of its pool of more than 145 000 UCB units was from racial and ethnic minorities. 25 In a recent study, Barker et al. 26 have demonstrated that UCB does increase access to allogeneic HCT for patients of all races and ethnicities. They prospectively evaluated the availability of unrelated donors and UCB based on patient ancestry by performing combined searches in 553 patients without sibling donors. A 10/10 HLA-matched unrelated donor was identified for 53% of patients of European ancestry, but only for 21% of patients of non-European origin; the majority of both groups had 5 --6/6 HLA-matched UCB units available for allografting. Continued efforts directed towards increasing the pool of high quality UCB units from racial and ethnic minorities are still needed. In an analysis using data submitted to the Center for International Blood and Marrow Transplant Research (CIBMTR), Ballen et al. 27 found that among recipients of single UCB transplantation, more Whites (40%) and Hispanics (42%) than Blacks (21%) received UCB units that were well-matched (5 --6/6 HLA-matched) and had an adequate cell dose (X2.5 Â 10 7 nucleated cells/kg recipient body weight).
Race and access to HCT HCT is most commonly performed for malignant hematologic disorders and the barriers that prevent access to cancer care for racial minorities are also relevant for HCT. Given that HCT is a complex and high-cost procedure, additional barriers may also have a role. The available literature on racial disparities in access to HCT is very limited (Table 1 ). Two relatively large database studies have addressed this issue. 28, 29 The first study used hospital discharge data from four states (California, Massachusetts, Maryland and New York) for two years (1988 and 1991) and used ICD-9 codes to identify 38 240 patients hospitalized with leukemia and lymphoma. 29 The authors found that after controlling for other factors, Black patients with leukemia were 51 --53% as likely and Black patients with lymphoma were 34 --45% as likely as Whites to undergo HCT (Po0.05). Medicaid patients were also significantly less likely to receive HCT compared with patients with private insurance. This was the first large study to address racial disparities in access to HCT; however, some shortcomings included the inclusion of hospitalized patients only and the use of medical codes for identifying patients, which can lack precision and have very limited details about disease-related prognostic factors.
The second more contemporaneous study was conducted by the CIBMTR and used data from the Surveillance, Epidemiology, and End Results program and the CIBMTR. 28 This analysis included data on an estimated 273 853 incident cases and an estimated 45 750 transplant recipients with ALL, AML, CML, non-Hodgkin's lymphoma and multiple myeloma treated during 1997 --2002. Compared with Blacks, the age-adjusted odds of receiving any type of HCT for all diseases considered was significantly higher for Whites (odds ratio ¼ 1.40, Po0.0001). For each transplant type (autologous, HLA-identical sibling and unrelated donor HCT), Whites had a significantly higher odds of receiving HCT than Blacks. These differences also held true for the majority of diseases studied. In addition to the limitations associated with registry studies, this study could not account for patient socioeconomic status. Possible limitations in study design notwithstanding, these studies highlight racial disparities in access to transplantation in the United States and show that Black patients in general have lesser access to HCT compared with White patients.
Race and outcomes of HCT Studies investigating the association of race and ethnicity with outcomes of HCT are summarized in Table 2 . 27,30 --36 For autologous HCT, studies have mainly focused on patients with multiple myeloma. Although limited by a small number of minority patients included in each study, the literature generally shows that Black patients who receive an autologous HCT for myeloma have OS comparable to that of White patients. 32 --34,36 In one of the largest studies to date, Hari et al. 32 used CIBMTR data to compare outcomes of 1892 White and 303 Black recipients of autologous HCT for myeloma. White and Black patients had similar probabilities of 5-year OS (47% vs 52%, P ¼ 0.19) and progression-free survival (21% vs 19%, P ¼ 0.64) as well as cumulative incidences of disease progression (72% vs 72%, P ¼ 0.97) and non-relapse mortality (8% vs 9%, P ¼ 0.52). In multivariate analyses, race was not associated with any of these outcomes. In contrast, racial disparities have been noted in outcomes of allogeneic HCT. 27, 30, 31, 35, 37 This may partly reflect the more complex nature and expense of allogeneic HCT compared with autologous HCT. In addition, biological factors may vary with ancestry and may at least partly contribute to differences in outcomes by race. For instance, differences in HLA and minor transplantation Ag diversity and frequencies of cytokine gene polymorphisms may explain some of the differences in risks of GVHD observed between patients of different ancestries. 38 --40 The largest analysis investigating association of race with outcomes of allogeneic HCT has been conducted by Baker status (median household income imputed by ZIP Code of residence), indicating that other biological, social or epidemiological factors could potentially be mediating overall mortality and treatment-related mortality. Race and outcomes of UCB transplantation are of particular interest as UCB has the potential to increase access to HLA-matched unrelated donors for patients from specific racial and ethnic groups. Only one study has looked at this issue and was conducted by Ballen et al. 27 using CIBMTR data. Outcomes were analyzed for 612 Whites, 145 Blacks and 128 Hispanics who underwent single UCB HCT between 1995 and 2006 for ALL, AML, myelodysplastic syndrome and CML. After adjusting for important patient and disease-related factors, Blacks had higher risks of overall mortality (RR 1.30, P ¼ 0.02), whereas survival of Hispanics was comparable to that of Whites. A significantly higher proportion of Blacks received units that were not well matched and had a low cell dose. On multivariate pair-wise comparisons, OS was similar among Blacks and Whites who received UCB units with adequate cell dose (X2.5 Â 10 7 nucleated cells/kg). Similarly, survival was comparable among Black and White patients who received 5--6/6 HLA-matched UCB units. These findings indicate that differences in survival after UCB HCT can at least partly be overcome by using units with higher cell dose and a closer HCT match in racial minorities and provides impetus for continued efforts to improve the quality of banked UCB units for these populations.
Is race a surrogate for other sociodemographic factors? In the field of biomedical research, race has been observed to be closely correlated with other social factors and these associations may modulate disease incidence and treatment outcomes. 3, 9, 11, 18 For example, Blacks have lower socioeconomic status, poorer health literacy and lower education status compared with Whites, and these social factors have been implicated for the poor quality of health and cancer care among the former. In this context, a question arises whether the observed racial differences in outcomes of HCT are a consequence of these same sociodemographic factors. Few studies have rigorously addressed this issue to date. Baker et al. 30 used ZIP Codes to estimate median household income for patients included in their study. The median household income was lower for Blacks compared with Whites. Probability of overall mortality and treatment-related mortality was inversely related to household income. By multivariate analysis, the effect of household income on overall mortality and treatment-related mortality was found to be independent of race. Similarly, the negative impact of Black race on outcomes was independent of household income. In a smaller study, Mielcarek et al. 35 performed a subset analysis to evaluate the association of race, education, household income, employment status and medicaid/social security eligibility with outcomes of allogeneic HCT. Blacks had higher risks of overall mortality compared with Whites and adjustment for various combinations of socioeconomic indicators did not change these risks noticeably. These studies indicate that socioeconomic status can explain only some of the differences in survival by race after allogeneic HCT and that more research is needed to identify other biological, social and cultural factors that may explain the reason for these disparities.
Areas for future research Three broad areas specific to HCT require more research on racial disparities: race and donor issues, race and access to HCT and race and outcomes of HCT (Table 3) .
Among medical treatments, HCT is unique because of the requirement of a suitable HLA-matched donor for transplantation. Several initiatives within the NMDP have increased the representation of donors from racial and ethnic minorities in the United States. However, we need more information on whether race and other social factors have any association with availability of unrelated donors. Race, donor availability and their impact on HCT outcomes also needs to be investigated. The number of US residents who identify themselves with more than one race represents another challenge to registry models that are built on 'one race --one person' concept; more research to better understand the changing demographics of the US population and its implications for donor recruitment and availability is needed.
Research is needed to further characterize causes for racial and ethnic disparities in access to HCT. Studies performed to date have used a variety of databases to address access issues. A more comprehensive assessment of geographic, social and cultural barriers to access to transplantation for patients belonging to minority racial groups is needed. Such studies will have to be performed at a patient and center level and will have to address inherent racial inequities due to biological and medical factors. For example, ethnic and racial minorities have a lower probability of finding a suitable donor and have a higher prevalence of comorbidities that may make them ineligible for transplantation. 41 --43 There are systemic issues with data collection and reporting practices with respect to race and ethnicity that need to be evaluated and addressed. Given that the expense of HCT procedure itself and the associated patient-related costs of undergoing transplantation (for example, transportation, time away from work, travel and lodging near center, deductibles and co-pays for outpatient medications) can be large, financial barriers may further accentuate racial disparities and need to be better understood. A related issue is family structure and support (for example, single parent households), which can be highly correlated with race and low socioeconomic status, and its association with access to and outcomes of HCT. Because of the complexity of HCT, health literacy also has the potential to influence access to and outcomes of transplantation and has not been well studied. Once etiologies of disparate access have been better characterized, studies evaluating targeted interventions to address these barriers are also needed. Better understanding of race-related factors that have an impact on outcomes of HCT are needed. Studies also need to investigate interventions to mitigate racial inequalities in post-transplant outcomes.
To eliminate racial disparities in the field of HCT, it is important that healthcare providers and transplant centers be aware of their existence. As we learn more about their causes and ways to eliminate them, the medical community including payors, policy makers, transplant centers and healthcare providers must use the current awareness of these inequalities to examine their own practices and work to eliminate inappropriate disparities in HCT.
